| Literature DB >> 29671873 |
Mathis Düster1, Martina Becker1, Ann-Christin Gnirck1, Malte Wunderlich1, Ulf Panzer1, Jan-Eric Turner1.
Abstract
Innate lymphoid cells (ILCs) are important regulators of the immune response and play a crucial role in the restoration of tissue homeostasis after injury. GATA-3+ IL-13- and IL-5-producing group 2 innate lymphoid cells (ILC2s) have been shown to promote tissue repair in barrier organs, but despite extensive research on ILCs in the recent years, their potential role in autoimmune diseases is still incompletely understood. In the present study, we investigate the role of ILC2s in the MRL/MpJ-Faslpr (MRL-lpr) mouse model for severe organ manifestation of systemic lupus erythematosus (SLE). We show that in these MRL-lpr mice, progression of lupus nephritis is accompanied with a reduction of ILC2 abundance in the inflamed renal tissue. Proliferation/survival and cytokine production of kidney-residing ILC2s was suppressed by IFN-γ and, to a lesser extent, by IL-27 which were produced by activated T cells and myeloid cells in the nephritic kidney, respectively. Most importantly, restoration of ILC2 numbers by IL-33-mediated expansion ameliorated lupus nephritis and prevented mortality in MRL-lpr mice. In summary, we show here that development of SLE-like kidney inflammation leads to a downregulation of the renal ILC2 response and identify an ILC2-expanding therapy as a promising treatment approach for autoimmune diseases.Entities:
Keywords: Autoimmunity; Cytokines; Innate lymphoid cells; MRL-lpr model; Systemic lupus erythematosus
Mesh:
Substances:
Year: 2018 PMID: 29671873 DOI: 10.1002/eji.201747303
Source DB: PubMed Journal: Eur J Immunol ISSN: 0014-2980 Impact factor: 5.532